Longitudinal change of clinical and biological measures in early Parkinson's disease: Parkinson's progression markers initiative cohort

Tanya Simuni, Andrew Siderowf, Shirley Lasch, Chris S. Coffey, Chelsea Caspell-Garcia, Danna Jennings, Caroline M. Tanner, John Q. Trojanowski, Leslie M. Shaw, John Seibyl, Norbert Schuff, Andrew Singleton, Karl Kieburtz, Arthur W. Toga, Brit Mollenhauer, Doug Galasko, Lana M. Chahine, Daniel Weintraub, Tatiana Foroud, Duygu TosunKathleen Poston, Vanessa Arnedo, Mark Frasier, Todd Sherer, Sohini Chowdhury, Kenneth Marek

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: The objective of this study was to assess longitudinal change in clinical and dopamine transporter imaging outcomes in early, untreated PD. Methods: We describe 5-year longitudinal change of the MDS-UPDRS and other clinical measures using results from the Parkinson's Progression Markers Initiative, a longitudinal cohort study of early Parkinson's disease (PD) participants untreated at baseline. We also provide data on the longitudinal change in dopamine transporter 123-I Ioflupane striatal binding and correlation between the 2 measures. Results: A total of 423 PD participants were recruited, and 358 remain in the study at year 5. Baseline MDS-UPDRS total score was 32.4 (standard deviation 13.1), and the average annual change (assessed medications OFF for the treated participants) was 7.45 (11.6), 3.11 (11.7), 4(11.9), 4.7 (11.1), and 1.74(11.9) for years 1, 2, 3, 4, and 5, respectively (P<.0001 for the change over time), with a steeper change in year 1. Dopaminergic therapy had a significant effect on the change of MDS-UPDRS. There was a significant longitudinal change in dopamine transporter binding in all striatal regions (P<.001). There was a significant but weak correlation between MDS-UPDRS and dopamine transporter binding at baseline and years 1, 2, and 4, but no correlation between the rate of change of the 2 variables. Conclusions: We present 5-year longitudinal data on the change of the MDS-UPDRS and other clinical and dopamine transporter imaging outcome measures in early PD. These data can be used for sample size estimates for interventional studies in the de novo PD population.

Original languageEnglish (US)
JournalMovement Disorders
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Dopamine Plasma Membrane Transport Proteins
Parkinson Disease
Disease Progression
Corpus Striatum
Sample Size
Longitudinal Studies
Cohort Studies
Outcome Assessment (Health Care)
Population

Keywords

  • Disease subtypes
  • Gait disorder predominant
  • Parkinson's disease
  • Postural instability
  • Tremor dominant

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Simuni, T., Siderowf, A., Lasch, S., Coffey, C. S., Caspell-Garcia, C., Jennings, D., ... Marek, K. (Accepted/In press). Longitudinal change of clinical and biological measures in early Parkinson's disease: Parkinson's progression markers initiative cohort. Movement Disorders. https://doi.org/10.1002/mds.27361

Longitudinal change of clinical and biological measures in early Parkinson's disease : Parkinson's progression markers initiative cohort. / Simuni, Tanya; Siderowf, Andrew; Lasch, Shirley; Coffey, Chris S.; Caspell-Garcia, Chelsea; Jennings, Danna; Tanner, Caroline M.; Trojanowski, John Q.; Shaw, Leslie M.; Seibyl, John; Schuff, Norbert; Singleton, Andrew; Kieburtz, Karl; Toga, Arthur W.; Mollenhauer, Brit; Galasko, Doug; Chahine, Lana M.; Weintraub, Daniel; Foroud, Tatiana; Tosun, Duygu; Poston, Kathleen; Arnedo, Vanessa; Frasier, Mark; Sherer, Todd; Chowdhury, Sohini; Marek, Kenneth.

In: Movement Disorders, 01.01.2018.

Research output: Contribution to journalArticle

Simuni, T, Siderowf, A, Lasch, S, Coffey, CS, Caspell-Garcia, C, Jennings, D, Tanner, CM, Trojanowski, JQ, Shaw, LM, Seibyl, J, Schuff, N, Singleton, A, Kieburtz, K, Toga, AW, Mollenhauer, B, Galasko, D, Chahine, LM, Weintraub, D, Foroud, T, Tosun, D, Poston, K, Arnedo, V, Frasier, M, Sherer, T, Chowdhury, S & Marek, K 2018, 'Longitudinal change of clinical and biological measures in early Parkinson's disease: Parkinson's progression markers initiative cohort', Movement Disorders. https://doi.org/10.1002/mds.27361
Simuni, Tanya ; Siderowf, Andrew ; Lasch, Shirley ; Coffey, Chris S. ; Caspell-Garcia, Chelsea ; Jennings, Danna ; Tanner, Caroline M. ; Trojanowski, John Q. ; Shaw, Leslie M. ; Seibyl, John ; Schuff, Norbert ; Singleton, Andrew ; Kieburtz, Karl ; Toga, Arthur W. ; Mollenhauer, Brit ; Galasko, Doug ; Chahine, Lana M. ; Weintraub, Daniel ; Foroud, Tatiana ; Tosun, Duygu ; Poston, Kathleen ; Arnedo, Vanessa ; Frasier, Mark ; Sherer, Todd ; Chowdhury, Sohini ; Marek, Kenneth. / Longitudinal change of clinical and biological measures in early Parkinson's disease : Parkinson's progression markers initiative cohort. In: Movement Disorders. 2018.
@article{99671e7ab2a3407689ad548cc39e5cf8,
title = "Longitudinal change of clinical and biological measures in early Parkinson's disease: Parkinson's progression markers initiative cohort",
abstract = "Objective: The objective of this study was to assess longitudinal change in clinical and dopamine transporter imaging outcomes in early, untreated PD. Methods: We describe 5-year longitudinal change of the MDS-UPDRS and other clinical measures using results from the Parkinson's Progression Markers Initiative, a longitudinal cohort study of early Parkinson's disease (PD) participants untreated at baseline. We also provide data on the longitudinal change in dopamine transporter 123-I Ioflupane striatal binding and correlation between the 2 measures. Results: A total of 423 PD participants were recruited, and 358 remain in the study at year 5. Baseline MDS-UPDRS total score was 32.4 (standard deviation 13.1), and the average annual change (assessed medications OFF for the treated participants) was 7.45 (11.6), 3.11 (11.7), 4(11.9), 4.7 (11.1), and 1.74(11.9) for years 1, 2, 3, 4, and 5, respectively (P<.0001 for the change over time), with a steeper change in year 1. Dopaminergic therapy had a significant effect on the change of MDS-UPDRS. There was a significant longitudinal change in dopamine transporter binding in all striatal regions (P<.001). There was a significant but weak correlation between MDS-UPDRS and dopamine transporter binding at baseline and years 1, 2, and 4, but no correlation between the rate of change of the 2 variables. Conclusions: We present 5-year longitudinal data on the change of the MDS-UPDRS and other clinical and dopamine transporter imaging outcome measures in early PD. These data can be used for sample size estimates for interventional studies in the de novo PD population.",
keywords = "Disease subtypes, Gait disorder predominant, Parkinson's disease, Postural instability, Tremor dominant",
author = "Tanya Simuni and Andrew Siderowf and Shirley Lasch and Coffey, {Chris S.} and Chelsea Caspell-Garcia and Danna Jennings and Tanner, {Caroline M.} and Trojanowski, {John Q.} and Shaw, {Leslie M.} and John Seibyl and Norbert Schuff and Andrew Singleton and Karl Kieburtz and Toga, {Arthur W.} and Brit Mollenhauer and Doug Galasko and Chahine, {Lana M.} and Daniel Weintraub and Tatiana Foroud and Duygu Tosun and Kathleen Poston and Vanessa Arnedo and Mark Frasier and Todd Sherer and Sohini Chowdhury and Kenneth Marek",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/mds.27361",
language = "English (US)",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Longitudinal change of clinical and biological measures in early Parkinson's disease

T2 - Parkinson's progression markers initiative cohort

AU - Simuni, Tanya

AU - Siderowf, Andrew

AU - Lasch, Shirley

AU - Coffey, Chris S.

AU - Caspell-Garcia, Chelsea

AU - Jennings, Danna

AU - Tanner, Caroline M.

AU - Trojanowski, John Q.

AU - Shaw, Leslie M.

AU - Seibyl, John

AU - Schuff, Norbert

AU - Singleton, Andrew

AU - Kieburtz, Karl

AU - Toga, Arthur W.

AU - Mollenhauer, Brit

AU - Galasko, Doug

AU - Chahine, Lana M.

AU - Weintraub, Daniel

AU - Foroud, Tatiana

AU - Tosun, Duygu

AU - Poston, Kathleen

AU - Arnedo, Vanessa

AU - Frasier, Mark

AU - Sherer, Todd

AU - Chowdhury, Sohini

AU - Marek, Kenneth

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: The objective of this study was to assess longitudinal change in clinical and dopamine transporter imaging outcomes in early, untreated PD. Methods: We describe 5-year longitudinal change of the MDS-UPDRS and other clinical measures using results from the Parkinson's Progression Markers Initiative, a longitudinal cohort study of early Parkinson's disease (PD) participants untreated at baseline. We also provide data on the longitudinal change in dopamine transporter 123-I Ioflupane striatal binding and correlation between the 2 measures. Results: A total of 423 PD participants were recruited, and 358 remain in the study at year 5. Baseline MDS-UPDRS total score was 32.4 (standard deviation 13.1), and the average annual change (assessed medications OFF for the treated participants) was 7.45 (11.6), 3.11 (11.7), 4(11.9), 4.7 (11.1), and 1.74(11.9) for years 1, 2, 3, 4, and 5, respectively (P<.0001 for the change over time), with a steeper change in year 1. Dopaminergic therapy had a significant effect on the change of MDS-UPDRS. There was a significant longitudinal change in dopamine transporter binding in all striatal regions (P<.001). There was a significant but weak correlation between MDS-UPDRS and dopamine transporter binding at baseline and years 1, 2, and 4, but no correlation between the rate of change of the 2 variables. Conclusions: We present 5-year longitudinal data on the change of the MDS-UPDRS and other clinical and dopamine transporter imaging outcome measures in early PD. These data can be used for sample size estimates for interventional studies in the de novo PD population.

AB - Objective: The objective of this study was to assess longitudinal change in clinical and dopamine transporter imaging outcomes in early, untreated PD. Methods: We describe 5-year longitudinal change of the MDS-UPDRS and other clinical measures using results from the Parkinson's Progression Markers Initiative, a longitudinal cohort study of early Parkinson's disease (PD) participants untreated at baseline. We also provide data on the longitudinal change in dopamine transporter 123-I Ioflupane striatal binding and correlation between the 2 measures. Results: A total of 423 PD participants were recruited, and 358 remain in the study at year 5. Baseline MDS-UPDRS total score was 32.4 (standard deviation 13.1), and the average annual change (assessed medications OFF for the treated participants) was 7.45 (11.6), 3.11 (11.7), 4(11.9), 4.7 (11.1), and 1.74(11.9) for years 1, 2, 3, 4, and 5, respectively (P<.0001 for the change over time), with a steeper change in year 1. Dopaminergic therapy had a significant effect on the change of MDS-UPDRS. There was a significant longitudinal change in dopamine transporter binding in all striatal regions (P<.001). There was a significant but weak correlation between MDS-UPDRS and dopamine transporter binding at baseline and years 1, 2, and 4, but no correlation between the rate of change of the 2 variables. Conclusions: We present 5-year longitudinal data on the change of the MDS-UPDRS and other clinical and dopamine transporter imaging outcome measures in early PD. These data can be used for sample size estimates for interventional studies in the de novo PD population.

KW - Disease subtypes

KW - Gait disorder predominant

KW - Parkinson's disease

KW - Postural instability

KW - Tremor dominant

UR - http://www.scopus.com/inward/record.url?scp=85044328192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044328192&partnerID=8YFLogxK

U2 - 10.1002/mds.27361

DO - 10.1002/mds.27361

M3 - Article

C2 - 29572948

AN - SCOPUS:85044328192

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

ER -